Stay updated on Galcanezumab in Chronic Migraine Ages 12-17 Clinical Trial

Sign up to get notified when there's something new on the Galcanezumab in Chronic Migraine Ages 12-17 Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Galcanezumab in Chronic Migraine Ages 12-17 Clinical Trial page

  1. Check
    7 days ago
    No Change Detected
  2. Check
    14 days ago
    No Change Detected
  3. Check
    21 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov page footer now identifies the site as revision v3.8.0 instead of v3.7.2.
    Difference
    0.0%
    Check dated 2026-10-31T15:14:10.000Z thumbnail image
  4. Check
    28 days ago
    Change Detected
    Summary
    A site-wide NIH notice announces a transition in terminology, saying federal agencies are using “Super Intelligence” in place of “Artificial Intelligence” during the transition.
    Difference
    0.3%
    Check dated 2026-10-24T14:41:43.000Z thumbnail image
  5. Check
    35 days ago
    Change Detected
    Summary
    The site footer revision changed from v3.7.1 to v3.7.2.
    Difference
    0.0%
    Check dated 2026-10-17T14:27:43.000Z thumbnail image
  6. Check
    42 days ago
    Change Detected
    Summary
    The site footer now displays revision v3.7.1 instead of v3.7.0.
    Difference
    0.0%
    Check dated 2026-10-10T14:29:48.000Z thumbnail image
  7. Check
    63 days ago
    Change Detected
    Summary
    A new site revision entry, v3.7.0, was added to the history, while the previous revision entry, v3.6.6, was removed.
    Difference
    0.0%
    Check dated 2026-09-19T19:05:43.000Z thumbnail image
  8. Check
    83 days ago
    Change Detected
    Summary
    The revision label on the page changed from v3.6.5 to v3.6.6. This reflects a software release for the site.
    Difference
    0.1%
    Check dated 2026-08-29T22:12:28.000Z thumbnail image

Stay in the know with updates to Galcanezumab in Chronic Migraine Ages 12-17 Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Galcanezumab in Chronic Migraine Ages 12-17 Clinical Trial page.